loading page

Efficacies of repurposing chloroquine analogues for the treatment of COVID-19: Facts and myths
  • Md. Abdul Alim Al-Bari
Md. Abdul Alim Al-Bari
University of Rajshahi
Author Profile

Abstract

The emergence of coronavirus disease 2019 (COVID-19) is caused by the 2019 novel coronavirus (2019-nCoV). The 2019-nCoV first broke out in Wuhan and subsequently spread worldwide owing to its extreme transmission efficiency. The fact that the COVID-19 cases and mortalities are reported in globally and the WHO has declared this outbreak as the pandemic. The international health authorities have focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the disease severity. Due to the lack of a known efficient therapy and public health emergency, repurposing drugs chloroquine (CQ) analogues appear to be the best tool against 2019-nCoV infection. These analogues have shown potential efficacy to inhibit 2019-nCoV in vitro that leads to focus in several new trials. This review discusses the possible effective roles and mechanisms of CQ analogues for interfering with the 2019-nCoV replication cycle and infection.